http://www.jnjbtw.com/2007/06/future-pharma/ Our People and Perspectives Wed, 08 Feb 2012 20:15:35 +0000 hourly 1 http://wordpress.org/?v=3.3 http://www.jnjbtw.com/2007/06/future-pharma/comment-page-1/#comment-26 Karl Darden Sat, 30 Jun 2007 00:14:46 +0000 http://jnjbtw.com/?p=49#comment-26 I agee with Steve. Sometimes I get a little frustrated with the Wall Street analysts and their desire to know more regarding all the details of the compounds in our pipeline. It might be a good idea to show them our Credo so they understand exactly where the investors fit into our company vision. For the patients sake, I think it is wise to tread lightly when it comes to the release of such information. I agee with Steve. Sometimes I get a little frustrated with the Wall Street analysts and their desire to know more regarding all the details of the compounds in our pipeline. It might be a good idea to show them our Credo so they understand exactly where the investors fit into our company vision. For the patients sake, I think it is wise to tread lightly when it comes to the release of such information.

]]> http://www.jnjbtw.com/2007/06/future-pharma/comment-page-1/#comment-25 Steve Woodruff Fri, 29 Jun 2007 19:27:11 +0000 http://jnjbtw.com/?p=49#comment-25 I think these investor groups need to bear in mind that not only is it inadvisable, from a competitive perspective, to say too much too early, but given the growing number of investor lawsuits, such a practice will put pharma companies on very dangerous footing. Many drug candidate failures don't show up until Phase 3 testing, and I can just imagine the frivolous shareholder lawsuits because the company will be accused of building up false hopes by revealing too-early data. Some cats really don't need to be out of the bag until a much clearer handle on safety and efficacy issues is established. I think these investor groups need to bear in mind that not only is it inadvisable, from a competitive perspective, to say too much too early, but given the growing number of investor lawsuits, such a practice will put pharma companies on very dangerous footing. Many drug candidate failures don’t show up until Phase 3 testing, and I can just imagine the frivolous shareholder lawsuits because the company will be accused of building up false hopes by revealing too-early data. Some cats really don’t need to be out of the bag until a much clearer handle on safety and efficacy issues is established.

]]>